CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Top player positioning
3.4.Porters five force analysis
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Rise in incidences of chronic diseases
3.5.1.2.Favorable regulatory scenario
3.5.1.3.Increase in geriatric population

3.5.2.Restraints

3.5.2.1.Availability of alternative therapies
3.5.2.2.Drug exploitation
3.5.2.3.Patent expiration of prescription drugs

3.5.3.Opportunity

3.5.3.1.Advancements in drug development
3.5.4.Impact Analysis

3.6.COVID-19 impact analysis for Gulf Pain Management Drugs

CHAPTER 4:GULF PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS

4.1.Overview

4.1.1.Market size and forecast

4.2.NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast

4.3.Anesthetics

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast

4.4.Anticonvulsants

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast

4.5.Antimigraine drug

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast

4.6.Antidepressants

4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast

4.7.Opioids

4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast

4.8.Non-narcotic analgesics

4.8.1.Key market trends, growth factors, and opportunities
4.8.2.Market size and forecast

CHAPTER 5:GULF PAIN MANAGEMENT DRUGS MARKET, BY INDICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Arthritic pain

5.2.1.Market size and forecast

5.3.Neuropathic pain

5.3.1.Market size and forecast

5.4.Cancer pain

5.4.1.Market size and forecast

5.5.Chronic back pain

5.5.1.Market size and forecast

5.6.Post-operative pain

5.6.1.Market size and forecast

5.7.Migraine

5.7.1.Market size and forecast

5.8.Fibromyalgia

5.8.1.Market size and forecast

5.9.Bone fracture

5.9.1.Market size and forecast

5.10.Muscle sprain/strain

5.10.1.Market size and forecast

5.11.Acute appendicitis

5.11.1.Market size and forecast

5.12.Others

5.12.1.Market size and forecast

CHAPTER 6:PAIN MANAGEMENT DRUGS, BY PAIN TYPE

6.1.Overview

6.1.1.Market size and forecast

6.2.Chronic pain

6.2.1.Market size and forecast

6.3.Acute pain

6.3.1.Market size and forecast

CHAPTER 7:GULF PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY

7.1.Overview

7.1.1.Market size and forecast

7.2.UAE

7.2.1.Key market trends and growth opportunities
7.2.2.Market size and forecast, by drug class
7.2.3.Market size and forecast, by indication
7.2.4.Market size and forecast, by pain type

7.3.Saudi Arabia

7.3.1.Key market trends and growth opportunities
7.3.2.Market size and forecast, by drug class
7.3.3.Market size and forecast, by indication
7.3.4.Market size and forecast, by pain type

7.4.Oman

7.4.1.Key market trends and growth opportunities
7.4.2.Market size and forecast, by drug class
7.4.3.Market size and forecast, by indication
7.4.4.Market size and forecast, by pain type

7.5.Rest of Gulf countries

7.5.1.Key market trends and growth opportunities
7.5.2.Market size and forecast, by drug class
7.5.3.Market size and forecast, by indication
7.5.4.Market size and forecast, by pain type

CHAPTER 8:COMPANY PROFILES

8.1.ABBOTT LABORATORIES

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance

8.2.ELI LILY AND COMPANY

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments

8.3.GLAXOSMITHKLINE PLC (GSK)

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance.
8.3.6.Key strategic moves and developments

8.4.JOHNSON & JOHNSON

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance

8.5.MERCK & CO., INC.

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments

8.6.MYLAN N.V.

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments

8.7.NOVARTIS INTERNATIONAL AG

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments

8.8.PFIZER INC.

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments

8.9.GULF PHARMACEUTICAL INDUSTRIES (JULPHAR)

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance

8.10.OMAN PHARMACEUTICAL PRODUCTS CO. LLC

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio